Toronto Dominion Bank raised its position in shares of Allergan PLC. (NYSE:AGN) by 25.2% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 113,770 shares of the company’s stock after acquiring an additional 22,873 shares during the period. Toronto Dominion Bank’s holdings in Allergan PLC. were worth $27,651,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of the business. Waldron LP bought a new position in shares of Allergan PLC. in the first quarter worth about $348,000. Neville Rodie & Shaw Inc. grew its holdings in shares of Allergan PLC. by 11.0% in the first quarter. Neville Rodie & Shaw Inc. now owns 3,074 shares of the company’s stock worth $734,000 after purchasing an additional 305 shares during the last quarter. Airain ltd bought a new position in shares of Allergan PLC. in the first quarter worth about $241,000. Ingalls & Snyder LLC grew its holdings in shares of Allergan PLC. by 20.6% in the first quarter. Ingalls & Snyder LLC now owns 1,254 shares of the company’s stock worth $300,000 after purchasing an additional 214 shares during the last quarter. Finally, BP PLC grew its holdings in shares of Allergan PLC. by 45.3% in the first quarter. BP PLC now owns 54,500 shares of the company’s stock worth $13,027,000 after purchasing an additional 17,000 shares during the last quarter. Institutional investors and hedge funds own 81.94% of the company’s stock.

Allergan PLC. (AGN) opened at 188.28 on Friday. The firm has a market cap of $62.94 billion, a P/E ratio of 5.74 and a beta of 1.15. Allergan PLC. has a 12-month low of $182.80 and a 12-month high of $256.80. The stock’s 50 day moving average is $211.30 and its 200 day moving average is $230.36.

Allergan PLC. (NYSE:AGN) last posted its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm’s revenue was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.35 earnings per share. On average, equities research analysts expect that Allergan PLC. will post $16.21 EPS for the current year.

Allergan PLC. announced that its board has authorized a stock repurchase program on Monday, September 25th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

WARNING: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/10/21/toronto-dominion-bank-has-27-65-million-holdings-in-allergan-plc-agn.html.

AGN has been the topic of a number of research analyst reports. Vetr raised shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price objective for the company in a research note on Monday, June 26th. BidaskClub raised shares of Allergan PLC. from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Zacks Investment Research raised shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price objective for the company in a research note on Tuesday, July 11th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $231.00 price objective on shares of Allergan PLC. in a research note on Friday, July 14th. Finally, Royal Bank Of Canada set a $284.00 price objective on shares of Allergan PLC. and gave the stock a “buy” rating in a research note on Sunday, July 16th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have issued a buy rating to the company. Allergan PLC. has an average rating of “Hold” and a consensus target price of $252.39.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.